Inhibition of FGFR4 increases oxaliplatin and 5-fluorouracil sensitivity in Kras wild-type and mutant colorectal cancer cells.

被引：0
|
作者：
Turkington, R. C.
Allen, W. L.
Stevenson, L.
Coyle, V.
Jithesh, P. V.
Proutski, I.
Fenning, C.
Stewart, G.
Van Schaeybroeck, S.
Longley, D.
Johnston, P. G.
机构：
[1] Queens Univ Belfast, Ctr Canc Res & Cell Biol, Belfast, Antrim, North Ireland
[2] Belfast City Hosp, Northern Ireland Canc Ctr, Belfast BT9 7AD, Antrim, North Ireland
[3] Queens Univ Belfast, Ctr Med Bioinformat, Belfast, Antrim, North Ireland
[4] Queens Univ Belfast, Belfast, Antrim, North Ireland
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2011年 / 29卷 / 15期
关键词：
D O I：
10.1200/jco.2011.29.15_suppl.e14087
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e14087
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Combination of FGFR4 inhibitor Blu9931 and 5-fluorouracil effects on the biological characteristics of colorectal cancer cells
    Jiang, Dongbao
    Li, Jingjing
    Li, Jie
    Wang, Min
    Han, Chao
    Wang, Xinru
    Zhao, Chunlin
    Ye, Yanwei
    INTERNATIONAL JOURNAL OF ONCOLOGY, 2017, 51 (05) : 1611 - 1620
  • [2] Oxaliplatin-Based Chemotherapy Is More Beneficial in KRAS Mutant than in KRAS Wild-Type Metastatic Colorectal Cancer Patients
    Lin, Yu-Lin
    Liang, Yi-Hsin
    Tsai, Jia-Huei
    Liau, Jau-Yu
    Liang, Jin-Tung
    Lin, Been-Ren
    Hung, Ji-Shiang
    Lin, Liang-In
    Tseng, Li-Hui
    Chang, Yih-Leong
    Yeh, Kun-Huei
    Cheng, Ann-Lii
    PLOS ONE, 2014, 9 (02):
  • [3] Tacalcitol increases the sensitivity of colorectal cancer cells to 5-fluorouracil by downregulating the thymidylate synthase
    Milczarek, Magdalena
    Rossowska, Joanna
    Klopotowska, Dagmara
    Stachowicz, Martyna
    Kutner, Andrzej
    Wietrzyk, Joanna
    JOURNAL OF STEROID BIOCHEMISTRY AND MOLECULAR BIOLOGY, 2019, 190 : 139 - 151
  • [4] Characterization of p53 wild-type and null isogenic colorectal cancer cell lines resistant to 5-fluorouracil, oxaliplatin, and irinotecan
    Boyer, J
    McLean, EG
    Aroori, S
    Wilson, P
    McCulla, A
    Carey, PD
    Longley, DB
    Johnston, PG
    CLINICAL CANCER RESEARCH, 2004, 10 (06) : 2158 - 2167
  • [5] miR-34a increases the sensitivity of colorectal cancer cells to 5-fluorouracil in vitro and in vivo
    Zhang, Qiyue
    Wang, Jingyuan
    Li, Na
    Liu, Zhentao
    Chen, Zuhua
    Li, Zhongwu
    Lai, Yumei
    Shen, Lin
    Gao, Jing
    AMERICAN JOURNAL OF CANCER RESEARCH, 2018, 8 (02): : 280 - +
  • [6] Comparative Proteomic Analysis of 5-Fluorouracil and Oxaliplatin Resistant Colorectal Cancer Cells
    Bose, D.
    Fan, F.
    Zimmerman, L.
    Slebbos, R.
    Parikh, A.
    Liebler, D.
    Ellis, L. M.
    ANNALS OF SURGICAL ONCOLOGY, 2010, 17 : S45 - S45
  • [7] Differential effects of 5-fluorouracil and oxaliplatin on autophagy in chemoresistant colorectal cancer cells
    Zitkute, Vilmante
    Kukcinaviciute, Egle
    Jonusiene, Violeta
    Starkuviene, Vytaute
    Sasnauskiene, Ausra
    JOURNAL OF CELLULAR BIOCHEMISTRY, 2022, 123 (06) : 1103 - 1115
  • [8] Antibody-dependent cellular cytotoxicity of cetuximab against colorectal cancer cells with wild-type and mutant KRAS
    Nakadate, Yusuke
    Kitamura, Yuka
    Tamura, Tomohide
    Koizumi, Fumiaki
    CANCER RESEARCH, 2012, 72
  • [9] CDK inhibitor enhances the sensitivity to 5-fluorouracil in colorectal cancer cells
    Takagi, Koichi
    Sowa, Yoshihiro
    Cevik, Ozgur Muhammer
    Nakanishi, Ryoko
    Sakai, Toshiyuki
    INTERNATIONAL JOURNAL OF ONCOLOGY, 2008, 32 (05) : 1105 - 1110
  • [10] Phase II trial of S-1 plus panitumumab for wild-type KRAS unresectable colorectal cancer patients previously treated with 5-fluorouracil (5-FU), oxaliplatin and irinotecan (KSCC1103)
    Sakamoto, Y.
    Yoshida, Y.
    Ishikawa, H.
    Ohchi, T.
    Takeshita, H.
    Emi, Y.
    Komatsu, H.
    Sawai, T.
    Shimose, T.
    Oki, E.
    Saeki, H.
    Kakeji, Y.
    Yoshida, Y.
    Baba, H.
    Maehara, Y.
    ANNALS OF ONCOLOGY, 2016, 27
12345